Liz Highleyman

The updates include new information on optimizing therapy, dealing with virological failure and managing opportunistic infections.

The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.

Alzheimer’s advocates laud the approval of Aduhelm, but experts raise questions about its effectiveness and cost.

The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.

Pioneering HIV doctor Paul Volberding and veteran activist Gregg Gonsalves reflect on the legacy of AIDS and its implications for COVID-19.

The new numbers are encouraging but Black and Latino people continue to be disproportionately affected by HIV.

The agency will accept public comment on the proposed guidelines during two webinars on May 24 and 25.

Several formulations of generic Truvada are now available at a lower cost.

Two experimental vaccine approaches, using mRNA protein delivery and germline targeting, are in the early stages of development.

A look at where we are 40 years into the HIV epidemic.

Treatment for the virus has come a long way since the first antiretroviral approval 1987, but more advances are yet still ahead.

Monitoring viral load and CD4 count can show how well treatment is working.

HIV was linked to an increased prevalence of liver fibrosis in a recent study.

A Brazilian man with HIV is no longer in remission after more than 15 months off treatment.

Study finds that Cabenuva administered every other month maintains viral suppression for two years.